Nephrology · Vol. 6, No. 1 · 2021 · pp. 16–21 · e-ISSN 2380-0445

Living Well with Kidney Disease by Patient and Care-Partner Empowerment: Kidney Health for Everyone Everywhere

Kamyar Kalantar-Zadeh, MD, MPH, PhD, Philip Kam-Tao Li, MD FRCP FACp, Ekamol Tantisattamo, MD, MPH, Latha Kumaraswami, BA, Vassilios Liakopoulos, MD, PhD, Siu-Fai Lui,MD, Ifeoma Ulasi, MD, Sharon Andreoli, MD, Alessandro Balducci, MD, Sophie Dupuis, MA, Tess Harris, MA, Anne Hradsky, MA, Richard Knight, MBA, Sajay Kumar, BCom, Maggie Ng, MA, Alice Poidevin, MA, Gamal Saadi, MD, Allison Tong, PhD

DOI: https://doi.org/10.17140/npoj-6-e012 · Published 2021-02-11 · Licence: https://creativecommons.org/licenses/by/4.0 · © 2021 The Author(s)

Also available as PDF (figures and tables appear in the PDF).

Abstract

Living with chronic kidney disease (CKD) is associated with hardships for patients and their care-partners. Empowering patients and their care-partners, including family members or friends involved in their care, may help minimize the burden and consequences of CKD related symptoms to enable life participation. There is a need to broaden the focus on living well with kidney disease and re-engagement in life, including an emphasis on patients being in control. The World Kidney Day (WKD) Joint Steering Committee has declared 2021 the year of “Living Well with Kidney Disease” in an effort to increase education and awareness on the important goal of patient empowerment and life participation. This calls for the development and implementation of validated patient-reported outcome measures to assess and address areas of life participation in routine care. It could be supported by regulatory agencies as a metric for quality care or to support labelling claims for medicines and devices. Funding agencies could establish targeted calls for research that address the priorities of patients. Patients with kidney disease and their care-partners should feel supported to live well through concerted efforts by kidney care communities including during pandemics. In the overall wellness program for kidney disease patients, the need for prevention should be reiterated. Early detection with a prolonged course of wellness despite kidney disease, after effective secondary and tertiary prevention programs, should be promoted. WKD 2021 continues to call for increased awareness of the importance of prevent

Keywords: concerted; prolonged; prevention

Conclusion

Effective strategies to empower patients and their care-partners strive to pursue the overarching goal of minimizing the burden of CKD related symptoms in order to enhance patient satisfaction, health-related quality of life, and life participation.World Kidney Day 2021 theme on “Living Well with Kidney Disease” is deliberately chosen to have the goals to redirect more focus on plans and actions towards achieving patient-centered wellness. Notwithstanding the COVID-19 pandemic that had overshadowed many activities in 2020 and beyond, the World Kidney Day Steering Committee has declared 2021 the year of “Living well with Kidney Disease” in an effort to increase education and awareness on the important goal of effective symptom management and patient empowerment. Whereas the World Kidney Day continues to emphasize the importance of effective measures to prevent kidney disease and its progression, patients with preexisting kidney disease and their carepartners should feel supported to live wellthrough concerted efforts by kidney care communities and other stakeholders throughout the world even during a world-shattering pandemic as COVID-19 that may drain many resources. Living well with kidney disease is an uncompromisable goal of all kidney foundations, patient groups, and professional societies alike, to which the International Society of Nephrology and the International Federation of Kidney FoundationWorld Kidney Alliance are committed at all times.

Acknowledgment

The authors has taken permission of reprinting this article in mutiple journals in order to spread awareness by the Steering Committee.

Conflicts Of Interest

K.K.-Z. reports honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, BBraun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. P.K.T.L. reports personal fees from Fibrogen and Astra-Zeneca. G.S. reports personal fees from Multicare, Novartis, Sandoz, and Astra- Zeneca. V.L. reports nonfinancial support from Genesis Pharma.

References

  1. TongAMannsBWangAYMHemmelgarnBWheelerDCGillJTugwellP. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int. 2018; 94(6): 1053- 1068. doi: 10.1016/j.kint.2018.08.01810.1016/j.kint.2018.08.018 https://doi.org/10.1016/j.kint.2018.08.018
  2. CarterSAGutmanTLogemanCCattranDLightstoneLBaggaA. Identifying outcomes important to patients with glomerular disease and their caregivers. Clin J Am Soc Nephrol. 2020; 15(5): 673-684. doi: 10.2215/CJN.1310101910.2215/cjn.13101019 https://doi.org/10.2215/cjn.13101019
  3. HansonCSCraigJCLogemanCSinhaADartAEddyAA. Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrology-Children and Adolescents (SONG-KIDS) consensus workshops. Kidney Int. 2020; 98(3): 553-565. doi: 10.1016/j.kint.2020.05.05410.1016/j.kint.2020.05.054 https://doi.org/10.1016/j.kint.2020.05.054
  4. GonzalezAMGutmanTLopez-VargasPAnumuduSArceCMCraigJC. Patient and caregiver priorities for outcomes in CKD: A multinational nominal group technique study. Am J Kid Dis. 2020; 76(5): 679-689. doi: 10.1053/j.ajkd.2020.03.02210.1053/j.ajkd.2020.03.022 https://doi.org/10.1053/j.ajkd.2020.03.022
  5. World Health Organization (WHO). Towards a common language for functioning, disability and health. 2002. Web site. https://www.who.int/classifications/icf/icfbeginnersguide.pdf. Accessed December 30, 2020
  6. World Health Organization (WHO). Health Promotion Glossary. 1998. Web site. https://www.who.int/healthpromotion/ about/HPG/en/. Accessed December 30, 2020
  7. BaumgartAManeraKEJohnsonDWCraigJCShenJIRuizL. Meaning of empowerment in peritoneal dialysis: focus groups with patients and caregivers. Nephrol Dial Transplant. 2020. doi: 10.1093/ndt/gfaa12710.1093/ndt/gfaa127 https://doi.org/10.1093/ndt/gfaa127
  8. Patient-Centered Outcomes Research Institute (PCORI). The Value of Engagement. 2018. Web site. https://www.pcori. org/about-us/our-programs/engagement/public-and-patientengagement/value-engagement. Accessed September 1, 2020
  9. BonventreJVHurstFPWestMWuIRoy-ChaudhuryPSheldonM. A technology roadmap for innovative approaches to kidney replacement therapies: A catalyst for change. Clin J Am Soc Nephrol. 2019; 14(10): 1539-1547. doi: 10.2215/CJN.0257031910.2215/cjn.02570319 https://doi.org/10.2215/cjn.02570319
  10. IbrahimNMichailMCallaghanP. The strengths based approach as a service delivery model for severe mental illness: a meta-analysis of clinical trials. BMC Psychiatry. 2014; 14: 243. doi: 10.1186/s12888-014-0243-610.1186/s12888-014-0243-6 https://doi.org/10.1186/s12888-014-0243-6
  11. ParhamRJacynaNHothiDMarksSDHolttumSCamicP. Development of a measure of caregiver burden in paediatric chronic kidney disease: The Paediatric Renal Caregiver Burden Scale.J Health Psychol. 2014; 21(2): 193-205. doi: 10.1177/135910531452497110.1177/1359105314524971 https://doi.org/10.1177/1359105314524971
  12. SubramanianLKirkRCuttittaTBryantNFoxKMcCallM. Remote management for peritoneal dialysis: A qualitative study of patient, care partner, and clinician perceptions and priorities in the United States and the United Kingdom. Kidney Med. 2019; 1(6): 354-365. doi: 10.1016/j.xkme.2019.07.01410.1016/j.xkme.2019.07.014 https://doi.org/10.1016/j.xkme.2019.07.014
  13. AngwenyiVAantjesCKajumiMDe ManJCrielBBunders-AelenJ. Patients experiences of self-management and strategies for dealing with chronic conditions in rural Malawi. PLoS One. 2018; 13(7): e0199977. doi: 10.1371/journal.pone.019997710.1371/journal.pone.0199977 https://doi.org/10.1371/journal.pone.0199977
  14. UlasiIIIjomaCK. The enormity of chronic kidney disease in Nigeria: The situation in a teaching hospital in South-East Nigeria. J Trop Med. 2010; 2010: 501957. doi: 10.1155/2010/50195710.1155/2010/501957 https://doi.org/10.1155/2010/501957
  15. SpinowitzBPecoits-FilhoRWinkelmayerWCPergolaPERochetteSThompson-LeducP. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ. 2019; 22(6): 593-604. doi: 10.1080/13696998.2019.158873810.1080/13696998.2019.1588738 https://doi.org/10.1080/13696998.2019.1588738
  16. SukulNSpeyerETuCBieberBALiYLopesAA. Pruritus and patient reported outcomes in non-dialysis CKD. Clin J Am Soc Nephrol. 2019; 14(5): 673-681. doi: 10.2215/CJN.0960081810.2215/cjn.09600818 https://doi.org/10.2215/cjn.09600818
  17. GreggLPHedayatiSS. Pharmacologic and psychological interventions for depression treatment in patients with kidney disease. Curr Opin Nephrol Hypertens. 2020; 29(5): 457-464. doi: 10.1097/MNH.000000000000062910.1097/mnh.0000000000000629 https://doi.org/10.1097/mnh.0000000000000629
  18. LiPKGarcia-GarciaGLuiSFAndreoliSFungWWHradskyA. Kidney health for everyone everywhere-from prevention to detection and equitable access to care. Kidney Int. 2020; 97(2): 226-232. doi: 10.1016/j.kint.2019.12.00210.1016/j.kint.2019.12.002 https://doi.org/10.1016/j.kint.2019.12.002
  19. Kalantar-ZadehKLiPK. Strategies to prevent kidney disease and its progression. Nat Rev Nephrol. 2020; 16(3): 129-130. doi: 10.1038/s41581-020-0253-110.1038/s41581-020-0253-1 https://doi.org/10.1038/s41581-020-0253-1
  20. Kalantar-ZadehKWightmanALiaoS. Ensuring choice for people with kidney failure-dialysis, supportive care, and hope. N Engl J Med. 2020; 383(2): 99-101. doi: 10.1056/NEJMp200179410.1056/nejmp2001794 https://doi.org/10.1056/nejmp2001794